Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults A Randomized Clinical Trial ++

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267?utm_medium=email&utm_source=govdelivery New CDER Research on the Effect of Cannabidiol on Liver Enzymes and Endocrine Measures Highlighted in CDER Impact Story Despite limited and inconsistent human safety data, unregulated cannabidiol (CBD) products are widely available to consumers. In this CDER Impact Story, CDER experts describe a randomized, double-blinded, placebo-controlled study demonstrating that CBD use at doses representative of consumer products is associated with liver enzyme elevations in 5.6% of healthy adults. The study findings have important regulatory implications that can inform discussions about appropriate safeguards and underscore the need for further investigation of the long-term effects of CBD use, its effects on various populations, and the safety of lower doses commonly used by consumers. CDER Investigators Address the Safety of CBD in a Randomized Trial https://www.fda.gov/drugs/regulatory-science-action/cder-investigators-address-safety-cbd-randomized-trial?utm_medium=email&utm_source=govdelivery